Literature DB >> 19107224

National Academy of Clinical Biochemistry (NACB) laboratory medicine guidelines on the clinical utilization and analytical issues for cardiac biomarker testing in heart failure.

John Beilby1.   

Abstract

Entities:  

Year:  2008        PMID： 19107224      PMCID： PMC2605411     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN： 0159-8090


× No keyword cloud information.
  22 in total

1.  Relation between cardiac troponin I and mortality in acute decompensated heart failure.

Authors:  John J You; Peter C Austin; David A Alter; Dennis T Ko; Jack V Tu
Journal:  Am Heart J       Date:  2007-04       Impact factor: 4.749

2.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure.

Authors:  Fred S Apple; Alan H B Wu; Allan S Jaffe; Mauro Panteghini; Robert H Christenson; Christopher P Cannon; Gary Francis; Robert L Jesse; David A Morrow; L Kristen Newby; Alan B Storrow; W H Wilson Tang; Franca Pagani; Jillian Tate; Jordi Ordonez-Llanos; Johannes Mair
Journal:  Circulation       Date:  2007-07-14       Impact factor: 29.690

3.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure.

Authors:  W H Wilson Tang; Gary S Francis; David A Morrow; L Kristin Newby; Christopher P Cannon; Robert L Jesse; Alan B Storrow; Robert H Christenson; Fred S Apple; Jan Ravkilde; Alan H B Wu
Journal:  Circulation       Date:  2007-07-14       Impact factor: 29.690

4.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.

Authors:  James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski
Journal:  Am J Cardiol       Date:  2005-04-15       Impact factor: 2.778

Review 5.  The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients.

Authors:  Rory O'Hanlon; Paula O'Shea; Mark Ledwidge; Christina O'Loughlin; Sophie Lange; Carmel Conlon; Dermot Phelan; Sean Cunningham; Ken McDonald
Journal:  J Card Fail       Date:  2007-02       Impact factor: 5.712

6.  Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.

Authors:  Bertil Lindahl; Johan Lindbäck; Tomas Jernberg; Nina Johnston; Mats Stridsberg; Per Venge; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2005-02-15       Impact factor: 24.094

7.  BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure.

Authors:  Luís Beck-da-Silva; Adolfo de Bold; Margaret Fraser; Kathryn Williams; Haissam Haddad
Journal:  Congest Heart Fail       Date:  2005 Sep-Oct

8.  Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure.

Authors:  Eduardo R Perna; Stella M Macín; Juan P Cimbaro Canella; Pablo M Alvarenga; Nelson G Ríos; Rolando Pantich; Natalia Augier; Eduardo F Farías; Eloísa Jantus; Monica Brizuela; Fernanda Medina
Journal:  Int J Cardiol       Date:  2005-03-18       Impact factor: 4.164

Review 9.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Authors:  Alan H B Wu
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

Review 10.  Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure.

Authors:  Serge Masson; Roberto Latini
Journal:  Am J Cardiol       Date:  2008-02-04       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.